What is Zolgensma 2 10*13 vg/ml inf. sol. i.v. vial used for?

( ARTG ) ZOLGENSMA (onasemnogene abeparvovec) is indicated for the treatment of paediatric patients with 5q spinal muscular atrophy (SMA) with bi-allelic mutations in the survival motor neuron 1 (SMN1) gene with 3 or fewer copies of the SMN2 gene. (Refer to Dosage and Method of Administration, section 4.2, Special Populations, paediatric patients and section 5.1 Clinical Trials).

What are the side effects of Zolgensma 2 10*13 vg/ml inf. sol. i.v. vial?

This medicine is under additional monitoring as it is new or being used in a different way. You can help identify new safety information by reporting any side effects you may get. You can report side effects to your doctor, or directly at www.tga.gov.au/reporting-problems . For more information on the Black Triangle Scheme and how to report side effects, see www.tga.gov.au/black-triangle-scheme

Can Zolgensma 2 10*13 vg/ml inf. sol. i.v. vial be used during pregnancy?

( AHT ) For the active ingredient onasemnogene abeparvovec You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.

What ATC class does Zolgensma 2 10*13 vg/ml inf. sol. i.v. vial belong to?

Zolgensma 2 10*13 vg/ml inf. sol. i.v. vial: ATC M09AX09 Onasemnogene Abeparvovec. ATC is the WHO Anatomical Therapeutic Chemical classification — it groups drugs by organ system and pharmacological mechanism.

OTC

Zolgensma 2 10*13 vg/ml inf. sol. i.v. vial

Solution for infusion

INN: Onasemnogene Abeparvovec 2 10*13 vg/ml

Data updated: 2026-04-11

Available in:

🇩🇪🇬🇧🇹🇷

Form

Solution for infusion

Dosage

—

Route

Intravenous use

Storage

—

About This Product

User Reviews

Reviews reflect personal experiences and are not medical advice. Always consult your doctor.